BetterLife Pharma Inc.

BETRFdata completeness 75%9 fiscal years on file
i. The business — what you’d actually own
FigureFY 2013FY 2015FY 2016FY 2017FY 2018
Revenue—————
Net income$341,4251−$1.13M2−$10.3M3−$6.28M4−$121,1824
Operating cash flow−$31,5865−$47,2576−$163,9427−$359,4498−$395,6028
Capital expenditure—————
Free cash flow (derived)—————
Total debt————$201,1759
Cash & equivalents$47510$83911$71,63912$112,42112$64,51112
Diluted shares35.8M11.6M77.7M75.6M82.4M

Superscripts are receipts. Each links to the SEC filing the number came from (full list at the bottom). A derived or summed figure cites every filing line it was built from.

ii. Your slice — ownership made literal
If you owned
shares
Net assets behind them
−$0.01
your share of equity
Profit it earned you last year
−$0.01
Free cash flow it threw off
—
Debt you’d be carrying
$0.02

10 shares is a claim on −$0.01 of net worth that earned you −$0.01 last year, against $0.02 of debt.

iii. Is this a good business?
Moat signal · return on equity
— avg · 5y

Not enough data in the filings for a return-on-capital reading.

seeing a moat in the numbers →
Management signal · capital allocation
+130% shares · 5y

Share count is up 130% over 5 years — owners have been diluted. Worth asking what they got for it. Total debt has held roughly steady.

reading capital allocation →

Signals, not verdicts — read from the filings above. Numbers don’t prove a moat; they show its footprint. You decide.

iv. What it’s worth — engine v0.6.0
not applicable
only 0 years of FCF (need ≥3) — model not applicable
not applicable
only 0 years of FCF (need ≥3) — model not applicable
not applicable
normalized (5y-median) earnings non-positive — EPV undefined
not applicable
diluted EPS missing or non-positive — Graham Number undefined

Different models answer different questions — which to trust when →

Beyond this page

This page is free, and so is every other company on MeritValue.

In your AI assistant

Connect the MeritValue MCP server to Claude or another MCP client, ask about BetterLife Pharma Inc., and get these exact figures with their filing receipts — not an improvised DCF.

Get a free key →
Screen by model

Pull the companies with a published value under any model (up to 500 a request, filtered by data completeness) into your own sheet or agent. Screening is what Analyst adds, at $9/month.

See pricing →
On iPhone

Follow BETRF and keep your own price beside the value. The same engine, with the same receipts.

MeritValue on the App Store →
Sources — the receipts
  1. 10-K filed 2013-05-16 · period ending 2013-01-31 · accession 0001511164-13-000237 (NetIncomeLoss)
  2. 10-K/A filed 2016-06-07 · period ending 2015-01-31 · accession 0001477932-16-010741 (NetIncomeLoss)
  3. 10-K filed 2017-04-28 · period ending 2016-01-31 · accession 0001477932-17-002007 (NetIncomeLoss)
  4. 10-K filed 2018-05-01 · periods ending 2017-01-31, 2018-01-31 · accession 0001477932-18-002135 (NetIncomeLoss)
  5. 10-K filed 2013-05-16 · period ending 2013-01-31 · accession 0001511164-13-000237 (NetCashProvidedByUsedInOperatingActivities)
  6. 10-K/A filed 2016-06-07 · period ending 2015-01-31 · accession 0001477932-16-010741 (NetCashProvidedByUsedInOperatingActivities)
  7. 10-K filed 2017-04-28 · period ending 2016-01-31 · accession 0001477932-17-002007 (NetCashProvidedByUsedInOperatingActivities)
  8. 10-K filed 2018-05-01 · periods ending 2017-01-31, 2018-01-31 · accession 0001477932-18-002135 (NetCashProvidedByUsedInOperatingActivities)
  9. 10-K filed 2018-05-01 · period ending 2018-01-31 · accession 0001477932-18-002135 (NotesPayable)
  10. 10-K filed 2013-05-16 · period ending 2013-01-31 · accession 0001511164-13-000237 (CashAndCashEquivalentsAtCarryingValue)
  11. 10-K filed 2017-04-28 · period ending 2015-01-31 · accession 0001477932-17-002007 (CashAndCashEquivalentsAtCarryingValue)
  12. 10-K filed 2018-05-01 · periods ending 2016-01-31, 2017-01-31, 2018-01-31 · accession 0001477932-18-002135 (CashAndCashEquivalentsAtCarryingValue)